C7744
溴他汀 A4
≥98% (HPLC), vascular disrupting agent, powder
别名:
1-（3,4,5-三甲氧基苯基）-2-（3′-羟基-4′-甲氧基苯基）乙烷 3,4,5-三甲氧基-3′-羟基-4′--甲氧基芪, 2-甲氧基-5-[(1Z)-2-（3,4,5-三甲氧基苯基）乙烯基] 苯酚, CA4
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C18H20O5
化学文摘社编号:
分子量:
316.35
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
溴他汀 A4, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
color
off-white
solubility
DMSO: >10 mg/mL
storage temp.
−20°C
SMILES string
COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O
InChI
1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-
InChI key
HVXBOLULGPECHP-WAYWQWQTSA-N
General description
考布他汀A4属于秋水仙碱类。
Application
考布他汀A4已被用于：
- 作为抗微管剂用于确定G2/M期异柠檬酸脱氢酶（IDH1和IDH2）蛋白的作用
- 评估联苯CA4衍生物在2D和3D癌细胞和非癌细胞模型中的的抗增生和促凋亡特性
- 作为微管抑制剂用于研究其对猪蛔虫L3幼虫的作用
Biochem/physiol Actions
考布他汀A4是一种强效的微管靶向剂。
Combretastatin A4是一种靶向肿瘤血管以抑制血管生成的血管分裂剂(VDA)。
Combretastatin A4是一种靶向肿瘤血管以抑制血管生成的血管分裂剂(VDA)。它在β-微管蛋白的秋水仙碱结合位点抑制微管蛋白聚合。它通过抑制人胃细胞中的AKT功能而具有抗肿瘤活性。被抑制的 AKT 激活引起细胞增殖下降，细胞周期停滞，在体外 迁移/侵袭和 体内 转移能力降低 。Combretastatin A4 是一种天然二苯乙烯类苯酚。
Still not finding the right product?
Explore all of our products under 溴他汀 A4
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Eric Y Huang et al.
Journal of cellular and molecular medicine, 22(7), 3661-3670 (2018-04-24)
Single nucleotide polymorphisms (SNPs) within the regulatory elements of a gene can alter gene expression, making these SNPs of prime importance for candidate gene association studies. We aimed to determine whether such regulatory variants are associated with clinical outcomes in
Lisa M Greene et al.
Biochemical pharmacology, 84(5), 612-624 (2012-06-19)
Recent clinical data demonstrated that the vascular targeting agent Combretastatin-A4 phosphate (CA-4P) prolonged survival of patients with advanced anaplastic thyroid cancer without any adverse side effects. However, as a single agent CA-4 failed to reduce tumour growth in the murine
Lasse Dührsen et al.
Journal of neurosurgery, 128(6), 1668-1673 (2017-07-29)
OBJECTIVE Temporal lobe epilepsy (TLE) is the most common type of pharmacoresistant focal epilepsy, for which anterior mesial temporal lobe resection (AMTLR) is a treatment option. Focal cortical dysplasia Type IIIa (FCD IIIa), a developmental lesion resulting from defects in
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| C7744-25MG | 04061833218167 |
| C7744-5MG | 04061833218174 |